Inhibition of cardiac hypertrophy by aromadendrin through down-regulating NFAT and MAPKs pathways

Area of Science:

• Cardiovascular Research
• Pharmacology
• Cell Biology

Background:

• Cardiac hypertrophy is an adverse response to pressure overload, increasing heart failure risk.
• Aromadendrin (ARO) exhibits anti-lipid peroxidation properties and potential for cardiovascular disease management.

Purpose of the Study:

• To investigate the protective effects of Aromadendrin (ARO) against cardiac hypertrophy.
• To elucidate the mechanisms underlying ARO's therapeutic potential in cardiac hypertrophy models.

Main Methods:

• Established cardiac hypertrophy models using phenylephrine in rat neonatal ventricular cardiomyocytes (RNVMs) and transverse aortic constriction (TAC) in mice.
• Assessed cardiomyocyte size, protein synthesis, cardiac function, ventricular mass, myocyte cross-sectional area, and gene expression (ANP, BNP, Myh7).
• Evaluated oxidative stress markers (Malondialdehyde, 4-HNE, GSH/GSSG ratio), NFAT translocation, and MAPK pathways.

Main Results:

• ARO treatment normalized cardiomyocyte size and protein synthesis in a concentration- and time-dependent manner.
• In vivo, ARO improved cardiac function, reduced hypertrophy indicators, and suppressed cardiac fibrosis.
• ARO mitigated oxidative stress, prevented NFAT nuclear translocation, and inhibited MAPK pathway activation.

Conclusions:

• Aromadendrin demonstrates significant protective effects against experimental cardiac hypertrophy.
• ARO's mechanisms involve reducing oxidative stress and inhibiting key signaling pathways.
• ARO shows promise as a novel therapeutic agent for pathological cardiac hypertrophy.